Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer

The pan-HER tyrosine kinase inhibitor (TKI) neratinib is therapeutically active against metastatic breast cancers harboring activating HER2 mutations, but responses are variable and often not durable. Here we demonstrate that recurrent HER2 mutations have differential effects on endocrine therapy re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalra, Rashi, Chen, Ching Hui, Wang, Junkai, Salam, Ahmad Bin, Dobrolecki, Lacey E., Lewis, Alaina, Sallas, Christina, Yates, Clayton C., Gutierrez, Carolina, Karanam, Balasubramanyam, Anurag, Meenakshi, Lim, Bora, Ellis, Matthew J., Kavuri, Shyam M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379360/
https://www.ncbi.nlm.nih.gov/pubmed/35736563
http://dx.doi.org/10.1158/0008-5472.CAN-21-3106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379360/
https://www.ncbi.nlm.nih.gov/pubmed/35736563
http://dx.doi.org/10.1158/0008-5472.CAN-21-3106

Ejemplares similares